Chronic Viral Hepatitis in Human Immunodeficiency Virus-infected Patients

Sili, Uluhan; Tekin, Aysun; Korten, Volkan

doi:10.4274/vhd.07279

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently bevacizumab was also USFDA certified for the treatment of liver cancer as adjunctive chemotherapy [ 13 ]. Drug interactions between bevacizumab and other agents used in the treatment of hepatitis B and C have been noted and therefore it is important to watch for drug-drug interactions, specifically in patients suffering from hepatitis [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Intestinal Perforation: A Rare Complication of Treatment With Bevacizumab

Adhikari¹,

Ghose²,

Tekin³

et al. 2021

Cureus

View full text Add to dashboard Cite

Bevacizumab, a monoclonal immunoglobulin-G1 antibody directed against vascular endothelial growth factor (VEGF), inhibits angiogenesis. Gastrointestinal perforation is a serious and often fatal adverse event related to bevacizumab use. Bevacizumab is indicated in the treatment of colorectal malignancies, certain subtypes of non-small cell lung carcinoma, metastatic renal cell carcinomas, and cervical cancers. It is also indicated in the treatment of recurrent glioblastoma (GBM) in adult patients as the sole treatment agent or in combination with other antineoplastic medications. We present a case of a patient on bevacizumab currently with glioblastoma multiforme and seizures, who was previously treated with radiation treatment and temozolomide. The patient presented to the emergency room with abdominal pain, seizures and was diagnosed to have an intestinal perforation.

show abstract

Section: Discussionmentioning

confidence: 99%